Regulatory Considerations

Handbook of Therapeutic Antibodies

Volumn 1, Issue , 2008, Pages 277-300

  Shapiro, Marjorie A ^a   Swann, Patrick G ^a   Hartsough, Melanie ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Administration; Companies; Considerations; Synagis; Toxicology

Indexed keywords

EID: 84889431303     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619740.ch12     Document Type: Chapter

References (42)

1. Bauer, B.A., Besch-Williford, C.L., Riley, L.K. (2004) Comparison of the mouse antibody production (MAP) assay and polymerase chain reaction (PCR) assays for the detection of viral contaminants. Biologicals 32: 177-182.
2. Boon, L., Holland, B., Gordon, W., Liu, P., Shiau, F., Shanahan, W., Reimann, K.A., Fung, M. (2002a) Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in nonhuman primates. Toxicology 172: 191-203.
3. Boon, L., Laman, J.D., Ortiz-Buijsse, A., den Hartog, M.T., Hoffenberg, S., Liu, P., Shiau, F., de Boer, M. (2002b) Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 174: 53-65.
4. Brorson, K., Swann, P.G., Lizzio, E., Maudru, T., Peden, K., Stein, K.E. (2001) Use of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus levels in mAb cell-culture and downstream processing. Biotechnol Prog 17: 188-196.
5. Brorson, K., Xu, Y., Swann, P.G., Hamilton, E., Mustafa, M., de Wit, C., Norling, L.A., Stein, K.E. (2002) Evaluation of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus in mAb cell-culture. Biologicals 30: 15-26.
6. Brorson, K., Krejci, S., Lee, K., Hamilton, E., Stein, K., Xu, Y. (2003) Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 82: 321-329.
7. Bugelski, P.J., Herzyk, D.J., Rehm, S., Harmsen, A.G., Gore, E.V., Williams, D.M., Maleeff, B.E., Badger, A.M., Truneh, A., O'Brien, S.R., Macia, R.A., Wier, P.J., Morgan, D.G., Hart, T.K. (2000) Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum Exp Toxicol 19: 230-243.
8. Bussiere, J.L. (2003) Animal models as indicators of immunogenicity of therapeutic proteins in humans. Dev Biol (Basel) 112: 135-139.
9. Chirino, A.J., Mire-Sluis, A. (2004) Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22: 1383-1391.
10. Clark, M. (2000) Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 21: 397-402.
11. Eldering, J.A., Felten, C., Veilleux, C.A., Potts, B.J. (2004) Development of a PCR method for mycoplasma testing of Chinese hamster ovary cell cultures used in the manufacture of recombinant therapeutic proteins. Biologicals 32: 183-193.
12. Food and Drug Administration (1987) Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-Product Endotoxin Test For Human and Animal Parenteral Drugs, Biological Products and Medical Devices. FDA.
13. Food and Drug Administration (1994) International Conference on Harmonisation: Guideline on detection of toxicity to reproduction for medicinal product. [Docket No. 93D-0140]. Federal Register 59: 48746-48752.
14. Food and Drug Administration (1995) Points to consider in the manufacture and testing of therapeutic products for human use derived from transgenic animal. [Docket No. 95D-0131]. Federal Register 60: 44036.
15. Food and Drug Administration (1996a) Guidance for industry; content and format of investigational new drug applications (INDs) for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived product. [Docket No. 95D-0386]. Federal Register 61: 1939-1940.
16. Food and Drug Administration (1996b) International Conference on Harmonisation: Final guideline on stability testing of biotechnological/biological products [Docket No. 93D-0139]. Federal Register 61: 36466-36469.
17. Food and Drug Administration (1997a) Points to consider in the manufacture and testing of monoclonal antibody products for human us. [Docket No. 94D-0259]. Federal Register 62: 9196-9197.
18. Food and Drug Administration (1997b) International Conference on Harmonisation: S6 Guidance on preclinical safety evaluation of biotechnology-derived product. [Docket No. 97D-0113]. Federal Register 62: 6515-61519.
19. Food and Drug Administration (1997c) International Conference on Harmonisation: Guidance on nonclinical safety studies for the conduct of human clinical trials for pharmaceutical. [Docket No. 97D-0147]. Federal Register 62: 62922.
20. Food and Drug Administration (1998a) International Conference on Harmonisation: Guidance on quality of biotechnological/biological products Q5D: Derivation and characterization of cell substrates used for the production of biotechnological/biological product. [Docket No. 97D-0159]. Federal Register 63: 50244-50249.
21. Food and Drug Administration (1998b) International Conference on Harmonisation: Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origi. [Docket No. 96D-0058]. Federal Register 63: 51074-51084.
22. Food and Drug Administration (2001) International Conference on Harmonisation: Guidance on S7A safety pharmacology studies for human pharmaceuticals. [Docket No. D-1407]. Federal Register 66: 36791-36792.
23. Food and Drug Administration (2002a) Draft Guidance for Industry: Drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animal. [Docket No. 02D324]. Federal Register 67: 57828-57829.
24. Food and Drug Administration (2002b) Guidance for Industry: Revised preventative measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood product. [Docket No. 97D-0318]. Federal Register 67: 2226-2227.
25. Food and Drug Administration (2002c) International Conference on Harmonisation: Draft revised guidance on Q1A(R) stability testing of new drug substances and product. [Docket No. 93D-0139]. Federal Register 65: 21446-21453.
26. Food and Drug Administration (2002d) Guidance concerning demonstration of comparability of human biological product. [Docket No. 96D-0132]. Federal Register 70: 37861-37862.
27. Food and Drug Administration (2005) International Conference on Harmonisation: Guidance on Q5 comparability of biotechnological/biological products subject to changes in their manufacturing proces. [Docket No. 2004D-0118]. Federal Register 59: 48746-48752.
28. Ghetie, V., Ward, E.S. (2002) Transcytosis and catabolism of antibody. Immunol Res 25: 97-113.
29. Glennie, M.J., Johnson, P.W. (2000) Clinical trials of antibody therapy. Immunol Today 21: 403-410.
30. Green, M. (2002) Comparability studies for human therapeutics, preclinical and pharmacokinetic aspects. In Comparability Studies for Human Plasma-Derived Therapeutics-Workshop. http://www.fda.gov/cbr/minutes/plasma053002.htm.
31. Griffiths, E. (1987) WHO Expert Committee on Biological Standardizatio. Highlights of the Meeting of October 1996. Biologicals 25: 339-362.
32. Karpas, A., Dremucheva, A., Czepulkowski, B.H. (2001) A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci USA 98: 1799-1804.
33. Klingbeil, C., Hsu, D.H. (1999) Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol Pathol 27: 1-3.
34. Kohler, G., Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
35. Mire-Sluis, A.R., Barrett, Y.C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S.J., Taniguchi, G., Wierda, D., Zuckerman, L.A. (2004) Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289: 1-16.
36. Reichert, J.M., Rosensweig, C.J., Faden, L.B., Dewitz, M.C. (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23: 1073-1078.
37. Serabian, M.A., Pilaro, A.M. (1999) Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol Pathol 27: 27-31.
38. Stein, K.E. (1997) Overcoming obstacles to monoclonal antibody product development and approval. Trends Biotechnol 15: 88-90.
39. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437: 1299-1320.
40. Trang, J.M. (1992) Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Ferraiolo, B., Mohler, M.A., Gloff, C.A. (eds) Protein Pharmacokinetics and Metabolism. New York: Plenum Press, pp. 223-270.
41. Treacy, G. (2000) Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 19: 226-228.
42. Wilson, N., Hardisty, J.H. (2001) Short-term, subchronic and chronic toxicology studies. In: Hayes, W. (ed.) Principles and Methods of Toxicology. Philadelphia, PA: Taylor and Francis, pp. 917-957.